Clotilde Guidetti, MD

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts; Child Neuropsychiatry Unit, Department of Neuroscience, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts

  • 6Articles
  • 26.3KReads
  • 2023–2025Active
  • 48Collaborators
  • 31Citations

About

Clotilde Guidetti, MD, is affiliated with the Department of Psychiatry at Massachusetts General Hospital in Boston and the Child Neuropsychiatry Unit at IRCCS Bambino Gesù Pediatric Hospital in Rome. Guidetti has published extensively on major depressive disorder (MDD), focusing on the efficacy, safety, and therapeutic response of esmethadone (REL-1017) and other treatment strategies for patients with treatment-resistant depression. The research includes clinical trials assessing pharmacological and neuromodulation interventions, as well as analyses of cognitive outcomes and quality of life in MDD patients. Frequent collaborators include Maurizio Fava, Andrea Mattarei, Franco Folli, Luca Pani, and Marco Pappagallo.

Publications

JCP
Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis
Original Research

Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis

October 6, 2025

Esmethadone may be a potentially safe and effective adjunctive treatment for patients with MDD and antidepressant tachyphylaxis.
, , , et al
JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.
, , , et al
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
JCP
Effect of Time From Onset of MDD on Response to Esmethadone
Original Research

Effect of Time From Onset of MDD on Response to Esmethadone

May 13, 2024

Esmethadone 25 and 50 mg were more effective in reducing depression scale scores in patients who had a shorter time since their first major depressive episode.
, , , et al
PCC
REL-1017 Effects on Cognition in MDD
Original Research

REL-1017 Effects on Cognition in MDD

February 14, 2023

REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe